Research & Development



  雲瑯笑道︰“李斯趙高不可能,會是誰呢?”   太宰先是一愣,接著就有些興致勃勃的樣子了,指著那道大門對雲瑯道︰“你這麼聰明,一定有法子徹底解除這里的機關吧?”2014中国体育彩票   雲瑯一定會說是勞動的時候。234期福利彩票3d开奖   太宰哼了一聲,取過雲瑯肩頭的牛頭就甩了出去,原本沖著太宰,雲瑯游過來的那條蛇,立刻就沖著滾動的牛頭滑過去了。   雲瑯一手摟著太宰瘦俏的肩膀道︰“你現在可以對我說了,我知道你說的每一個字都是真的,對瑰寶的每一個形容都是不合適的,不管你用多麼優美的文字跟話語,也無法形容它的美麗于萬一!”2014彩票销售额   雲瑯不知道自己昨天晚上給了太宰多少承諾,反正,天亮之後他就後悔了……

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo